Eplerenone cuts death and hospitalization rates among patients fighting less severe but chronic forms of the condition
CHICAGO — People with mild heart failure symptoms may benefit from a drug previously reserved for patients with more severe forms of the condition or high blood pressure. The drug, called eplerenone, reduces the risk of hospitalization and death in patients with a milder, chronic form of heart failure, a new study finds. Physician Faiez Zannad of the Nancy University Hospital Center in Nancy, France, presented the findings November 14 at a meeting of the American Heart Association.
Zannad and his colleagues randomly assigned 2,737 patients, average age 69, to get either eplerenone or a placebo. After the groups had been followed for 21 months on average, the trial was stopped when it became clear the drug benefited those taking it. During follow-up 26 percent of people getting the placebo were hospitalized for heart failure or died from cardiovascular causes compared with only 18 percent of those getting the drug.
Heart failure occurs when the heart struggles